BioCardia
BCDA
26 hedge funds and large institutions have $3.1M invested in BioCardia in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
169% more call options, than puts
Call options by funds: $78K | Put options by funds: $29K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
8% more funds holding
Funds holding: 24 → 26 (+2)
0.23% less ownership
Funds ownership: 1.05% → 0.82% (-0.23%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
43% less capital invested
Capital invested by funds: $5.49M → $3.1M (-$2.38M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$58.3K |
| 2 |
Millennium Management
New York
|
+$45.2K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$20.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.08K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$1.11M |
| 2 |
BlackRock
New York
|
-$72K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$41.5K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$4.21K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$934 |
BCDA Hedge Fund Activity: Q2 2022 in Review
26 of the 5,958 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q2 2022, worth a combined $3.1M — down 43% from $5.49M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BCDA positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $58.3K. The largest seller was Roumell Asset Management, exiting entirely with an estimated $1.11M sold.
- 26 institutional investors held BioCardia (BCDA) as of Q2 2022, up from 24 in Q1 2022.
- Funds reported $3.1M of BioCardia stock for Q2 2022, down 43% quarter-over-quarter.
- 4 funds opened new BioCardia positions in Q2 2022 and 2 closed out, a net change of +2 holders.
- The largest BioCardia buyer in Q2 2022 was Susquehanna International Group, an estimated $58.3K added.
- The largest BioCardia seller in Q2 2022 was Roumell Asset Management, an estimated $1.11M sold.
Based on aggregated 13F filings for Q2 2022.